BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 11, 2026
Home » Topics » Medical technology, Regulatory

Medical technology, Regulatory
Medical technology, Regulatory RSS Feed RSS

Costa Rican flag, economy/growth puzzle pieces

Costa Rica designs tailor-made programs to train manpower for the med-tech sector

Feb. 28, 2020
By Sergio Held
SAN JOSE, Costa Rica – Two decades ago, the Costa Rican economy was basically an agriculture-based economy. Since then, the tiny Central American country has emerged as the second-largest med-tech exporter in the region as well as an eager partner and supplier of skilled manpower.
Read More

Regulatory front for Feb. 27, 2020

Feb. 27, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: King Systems.
Read More
FDA icons

FDA wraps up CLIA-related guidances for 510(k) diagnostics

Feb. 27, 2020
By Mark McCarty
The U.S. FDA has finalized two guidances dealing with class II tests that are subject to Medicare regulations, including the so-called dual CLIA waiver guidance. The agency said it will hold an April 14, 2020, webinar to go over both guidances, allocating 90 minutes to deal with questions about the two documents.
Read More
2-26-Butterfly-Network-iQ-ultrasound.png

Speakers make case for home-use ultrasound with help of AI

Feb. 26, 2020
By Mark McCarty
The second day of the FDA workshop on artificial intelligence (AI) in health care featured several interesting proposals, including that AI will be used in health care without the aid of a health care professional. John Martin, chief medical officer at Butterfly Network Inc., of Guildford, Conn., said the time is ripe for AI-assisted ultrasound in the home, which he claimed could reduce rehospitalizations in heart failure, one of the holy grails in U.S. government efforts to restrain health care spending growth.
Read More

Regulatory front for Feb. 26, 2020

Feb. 26, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Livanova.
Read More
Architectural pillars

Judge orders HHS to fill 10-year data gap on Clinicaltrials.gov

Feb. 26, 2020
By Mari Serebrov
While the staff at the U.S. Department of Health and Human Services (HHS) is currently all hands-on-deck in responding to the COVID-19 outbreak, some of the agencies in the department may have to divert resources to get sponsors of drug and device clinical trials to fill in nearly a decade-long data gap on Clinicaltrials.gov. That’s if a judge’s decision handed down this week stands.
Read More
French flags on building

Med-tech companies in France suffering from regulatory inertia in their home market

Feb. 25, 2020
By Bernard Banga
PARIS – The Syndicat National de l'Industrie des Technologies Médicales (SNITEM), the French national association of medical technology manufacturers, has just released a study looking at the development of this industrial sector in that country. This snapshot, produced every two years by the firm D&Consultants SAS on behalf of Courbevoie, France-based SNITEM and the bank Bpifrance SA, is based on a dual quantitative and qualitative approach.
Read More

FDA aims to navigate treacherous AI regulatory waters

Feb. 25, 2020
By Mark McCarty
Developers of artificial intelligence (AI) algorithms have their own nightmares to deal with, but the FDA is charged with employing a regulatory touch that steers clear of rocky shoals on one side and inescapable whirlpools on the other. The FDA’s Bakul Patel said during a Feb. 25 workshop that the FDA would quickly be swamped if the agency took a traditional regulatory approach to managing the super-iterative digital health space, but that the agency will keep a keen eye on the potential impact on patients as AI begins to move into clinical practice.
Read More
2-25-Fresenius-Novalung.png

FDA clears Novalung, the first ECMO system for long-term use

Feb. 25, 2020
By Liz Hollis
The U.S. FDA has given its nod to Novalung, a heart and lung support system from Fresenius Medical Care North America (FMCNA) for the treatment of acute respiratory or cardiopulmonary failure. The Waltham, Mass.-based company noted that Novalung is the first extracorporeal membrane oxygenation (ECMO) system to be cleared for more than six hours of use.
Read More

Regulatory front for Feb. 25, 2020

Feb. 25, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Tytek Medical.
Read More
Previous 1 2 … 413 414 415 416 417 418 419 420 421 … 445 446 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 10, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • Connecting puzzle pieces

    Korsana boosts Alzheimer’s work with reverse merger, $380M financing

    BioWorld Science
    Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing